Most Popular
-
1
S. Koreans' happiness rising slowly but surely: presidential panel
-
2
No. of depression patients exceeds 1m in 2022
-
3
Seoul subway fare to rise 12% beginning Saturday
-
4
Races tighten in Seoul as parties battle for Assembly control
-
5
Korean Air to submit new merger plan to ease antitrust concerns
-
6
Korea to begin experiment with central bank digital currency
-
7
6-year-old Uzbek girl found dead in Daegu
-
8
US House votes to remove Speaker Kevin McCarthy
-
9
US calls on China to encourage N. Korea's return to diplomacy
-
10
Star lecturers, hagwon probed over buying Suneung questions
SK bioscience's COVID-19 vaccine wins approval in Britain
By YonhapPublished : May 30, 2023 - 10:22
SK bioscience Co., a pharmaceutical affiliate of South Korea's SK Group, said Tuesday its COVID-19 vaccine SKYCovione has won approval from British authorities.
The British Medicines and Healthcare products Regulatory Agency has approved the Korean vaccine for use as a primary vaccination in those aged 18 and over in the United Kingdom, according to the company.
SK bioscience said it is SKYCovione's first permission outside Korea and it has become the eighth COVID-19 vaccine authorized by the British medicine regulator.
SKYCovione, South Korea's first homegrown vaccine, is a recombinant-protein vaccine based on novel two-component nanoparticles that can maximize immune efficiency. It was approved by the Korean drug safety authorities in June last year.
SK bioscience said it will seek the vaccine's World Health Organization emergency use listing to help ensure its global use. (Yonhap)
